Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
MediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special Meeting
June 11, 2025 17:49 ET | Source: MediPharm Labs Corp. TORONTO, June…
